# Kronos Worldwide Inc: overview

KRO · NYSE · CIK 1257640 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kro.md) · [Financials](/companies/kro/financials.md) · [Filings](/companies/kro/filings.md) · [Insiders](/companies/kro/insiders.md)

Latest reported revenue: [$558.1m](/filings/0001104659-26-091093.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091093).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [485](/filings/0001104659-25-107746.md) | [423 d](/filings/0001104659-26-025219.md) | [490](/filings/0001104659-26-056246.md) | [494](/filings/0001104659-26-091093.md) | [457](/filings/0001104659-25-107746.md) | [418 d](/filings/0001104659-26-025219.md) | [510](/filings/0001104659-26-056246.md) | [558](/filings/0001104659-26-091093.md) |
| Gross margin | % | [20.9%](/filings/0001104659-25-107746.md) | [20.4% d](/filings/0001104659-26-025219.md) | [21.8%](/filings/0001104659-26-056246.md) | [12.7%](/filings/0001104659-26-091093.md) | [10.3%](/filings/0001104659-25-107746.md) | [(0.9%) d](/filings/0001104659-26-025219.md) | [16.3%](/filings/0001104659-26-056246.md) | [18.4%](/filings/0001104659-26-091093.md) |
| Operating margin | % | [8.0%](/filings/0001104659-25-107746.md) | [6.8% d](/filings/0001104659-26-025219.md) | [7.8%](/filings/0001104659-26-056246.md) | [1.5%](/filings/0001104659-26-091093.md) | [(4.2%)](/filings/0001104659-25-107746.md) | [(15.1%) d](/filings/0001104659-26-025219.md) | [2.5%](/filings/0001104659-26-056246.md) | [6.7%](/filings/0001104659-26-091093.md) |
| Net margin | % | [14.8%](/filings/0001104659-25-107746.md) | [(3.1%) d](/filings/0001104659-26-025219.md) | [3.7%](/filings/0001104659-26-056246.md) | [(1.9%)](/filings/0001104659-26-091093.md) | [(8.1%)](/filings/0001104659-25-107746.md) | [(19.8%) d](/filings/0001104659-26-025219.md) | [(0.9%)](/filings/0001104659-26-056246.md) | [2.7%](/filings/0001104659-26-091093.md) |
| Diluted EPS | $ per share | [0.62](/filings/0001104659-25-107746.md) | not reported | [0.16](/filings/0001104659-26-056246.md) | [(0.08)](/filings/0001104659-26-091093.md) | [(0.32)](/filings/0001104659-25-107746.md) | not reported | [(0.04)](/filings/0001104659-26-056246.md) | [0.13](/filings/0001104659-26-091093.md) |
| Free cash flow | $m | [19.2 d](/filings/0001104659-25-107746.md) | [37.0 d](/filings/0001104659-26-025219.md) | [(114)](/filings/0001104659-26-056246.md) | [9.5 d](/filings/0001104659-26-091093.md) | [(17.4) d](/filings/0001104659-25-107746.md) | [81.9 d](/filings/0001104659-26-025219.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,939](/filings/0001558370-24-002607.md) | [1,930](/filings/0001558370-25-002395.md) | [1,667](/filings/0001104659-26-025219.md) | [1,887](/filings/0001104659-26-025219.md) | [1,859](/filings/0001104659-26-025219.md) |
| Gross margin | % | [23.0%](/filings/0001558370-24-002607.md) | [20.3%](/filings/0001558370-25-002395.md) | [9.9%](/filings/0001104659-26-025219.md) | [19.0%](/filings/0001104659-26-025219.md) | [11.5%](/filings/0001104659-26-025219.md) |
| Operating margin | % | [9.6%](/filings/0001558370-24-002607.md) | [8.3%](/filings/0001558370-25-002395.md) | [(3.4%)](/filings/0001104659-26-025219.md) | [6.5%](/filings/0001104659-26-025219.md) | [(2.0%)](/filings/0001104659-26-025219.md) |
| Net margin | % | [5.8%](/filings/0001558370-24-002607.md) | [5.4%](/filings/0001558370-25-002395.md) | [(2.9%)](/filings/0001104659-26-025219.md) | [4.6%](/filings/0001104659-26-025219.md) | [(6.0%)](/filings/0001104659-26-025219.md) |
| Diluted EPS | $ per share | [0.98](/filings/0001558370-24-002607.md) | [0.90](/filings/0001558370-25-002395.md) | [(0.43)](/filings/0001104659-26-025219.md) | [0.75](/filings/0001104659-26-025219.md) | [(0.96)](/filings/0001104659-26-025219.md) |
| Free cash flow | $m | [148](/filings/0001558370-24-002607.md) | [18.5](/filings/0001558370-25-002395.md) | [(41.9)](/filings/0001104659-26-025219.md) | [43.0](/filings/0001104659-26-025219.md) | [(40.4)](/filings/0001104659-26-025219.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kro/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2010-09-13 | [Simmons Harold C](/insiders/1037854.md) | Chairman of the Board, Director, Officer, 10% owner | Purchase (P) | 431 | $34.90 | $15.0k | [Form 4](/filings/0001257640-10-000027.md) |
| 2010-09-13 | [Simmons Harold C](/insiders/1037854.md) | Chairman of the Board, Director, Officer, 10% owner | Purchase (P) | 69 | $34.85 | $2.4k | [Form 4](/filings/0001257640-10-000027.md) |
| 2010-09-13 | [Simmons Harold C](/insiders/1037854.md) | Chairman of the Board, Director, Officer, 10% owner | Purchase (P) | 400 | $34.50 | $13.8k | [Form 4](/filings/0001257640-10-000027.md) |
| 2010-09-13 | [Simmons Harold C](/insiders/1037854.md) | Chairman of the Board, Director, Officer, 10% owner | Purchase (P) | 400 | $34.00 | $13.6k | [Form 4](/filings/0001257640-10-000027.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $19.5m | 3,075,895 |  | Added +89,859 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $18.1m | 2,854,962 |  | Reduced −262,890 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.9m | 1,719,820 |  | Added +81,573 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.2m | 981,241 |  | Added +11,036 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $5.0m | 794,684 |  | Reduced −9,904 |
| [Russell Investments Group, Ltd.](/funds/1692234.md) | 2026-06-30 | $4.2m | 665,745 |  | Reduced −63,768 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $3.8m | 604,734 |  | Added +295,971 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.7m | 577,631 |  | Added +16,076 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.5m | 557,132 |  | Reduced −22,300 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.3m | 522,591 |  | Added +15,782 |

## Recent filings

[All 724 filings](/companies/kro/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:16 ET | [8-K](/filings/0001257640-26-000029.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001257640-26-000029 |
| 2026-08-05 | 16:11 ET | [10-Q](/filings/0001104659-26-091093.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091093 |
| 2026-05-13 | 16:16 ET | [8-K](/filings/0001257640-26-000026.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001257640-26-000026 |
| 2026-05-06 | 16:16 ET | [8-K](/filings/0001257640-26-000023.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001257640-26-000023 |
| 2026-05-06 | 16:10 ET | [10-Q](/filings/0001104659-26-056246.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056246 |
| 2026-03-24 | 16:18 ET | [DEF 14A](/filings/0001257640-26-000016.md) | Proxy statement, period 2026-05-13 | 0001257640-26-000016 |
| 2026-03-09 | 16:17 ET | [8-K](/filings/0001257640-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001257640-26-000008 |
| 2026-03-09 | 16:11 ET | [10-K](/filings/0001104659-26-025219.md) | Annual report, period 2025-12-31 | 0001104659-26-025219 |
| 2026-02-25 | 16:16 ET | [8-K](/filings/0001257640-26-000004.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001257640-26-000004 |
| 2025-11-06 | 16:25 ET | [8-K](/filings/0001257640-25-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001257640-25-000041 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-025219.md), filed Mar 9, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d83059f2-edb2-46d0-b53c-266f1848eae3)

## About the filer

- CIK: 1257640
- Tickers: KRO
- Exchange: NYSE
- SIC code: 2810 Industrial Inorganic Chemicals
- State of incorporation: not reported
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.